CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 243069-243303 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1901","span":{"begin":0,"end":234},"obj":"Sentence"},{"id":"T54049","span":{"begin":0,"end":234},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Since the number of new intravenous agents with activity against Gram-negative organisms is extremely limited, the development of a new carbapenem may help to reduce the mortality, morbidity, and cost of serious nosocomial infections."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T366","span":{"begin":0,"end":234},"obj":"Sentence"}],"text":"Since the number of new intravenous agents with activity against Gram-negative organisms is extremely limited, the development of a new carbapenem may help to reduce the mortality, morbidity, and cost of serious nosocomial infections."}

{"project":"Epistemic_Statements","denotations":[{"id":"T531","span":{"begin":0,"end":234},"obj":"Epistemic_statement"}],"text":"Since the number of new intravenous agents with activity against Gram-negative organisms is extremely limited, the development of a new carbapenem may help to reduce the mortality, morbidity, and cost of serious nosocomial infections."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T885","span":{"begin":212,"end":233},"obj":"Disease"},{"id":"T27590","span":{"begin":212,"end":233},"obj":"Disease"}],"attributes":[{"id":"A885","pred":"mondo_id","subj":"T885","obj":"http://purl.obolibrary.org/obo/MONDO_0043544"},{"id":"A84187","pred":"mondo_id","subj":"T27590","obj":"http://purl.obolibrary.org/obo/MONDO_0043544"}],"text":"Since the number of new intravenous agents with activity against Gram-negative organisms is extremely limited, the development of a new carbapenem may help to reduce the mortality, morbidity, and cost of serious nosocomial infections."}